76328-94-4

Usage

Uses

Used in Pharmaceutical Industry:
6-chlorohexa-1-en-3-one serves as an essential intermediate in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and medications.
Used in Flavor and Fragrance Industry:
As a key component in the creation of flavoring agents, 6-chlorohexa-1-en-3-one is employed to enhance the taste and aroma of food products, beverages, and perfumes.
Used in Organic Synthesis:
6-chlorohexa-1-en-3-one acts as a versatile reagent in organic synthesis, enabling the production of a wide range of chemical compounds for various applications.
Used in Chemical Research:
In the field of chemical research, 6-chlorohexa-1-en-3-one is utilized to study and understand the properties and reactions of haloenones, furthering scientific knowledge and innovation.

Downstream Products

• 174790-35-3 3-bromo-5,6-dihydro-4H-pyrrolo<1,2-b>pyrazole 
• 1314138-13-0 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 
• 1426535-54-7 3-(4-chlorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 
• 10183-74-1 withasomnine 

Relevant academic research and scientific papers

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

Dihydropyrrolo[1,2-b]pyrazoles: Withasomnine and related compounds

In the paper we indicate the increasing importance of derivatives containing a dihydropyrrolo[1,2-b]pyrazole (DPP) core. We try to show our synthetic approach based on an improved Kulinkovich method as well as our new synthetic pathway. A complex methodology involving the preparation of substituted DPPs focuses on withasomnine and the synthesis of several structurally related compounds. The developed reaction protocols enable the preparation of the mentioned bicyclic system with broadly diverse substitution. Thus, we are able to prepare systems with aliphatic, aromatic, polyaromatic, heteroaromatic, TMS, and even adamantane substitution with known biologically active properties. The reaction protocol, consisting of two multi-step synthetic pathways, includes Sonogashira and Suzuki-Miyaura cross-coupling reactions, allenyl synthon formation, Kulinkovich cyclopropanation, ring transformations, and nonsymmetrical homoallenyl azines cycloadditions. Moreover, we prepared compounds with a resemblance to other bioactive species: fadrozole, nagstatine, an antitumor agent LY2109761 and a mixed lineage kinase 7 inhibitor DHP-2.

PYRAZOLYL DERIVATIVES AS SYK INHIBITORS

The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

New synthetic route to the alkaloid withasomnine by ring transformation of a functionalized cyclopropanol via the parent pyrrolo[1,2-b]pyrazole

Withasomnine has been prepared by rearrangement of 1-(3-chloropropyl)-cyclopropanol into 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole, followed by bromination and [NiCl2(dppp)]-catalyzed phenylation.